ArticleFrontiers in medicine2026
Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, accidental injury has emerged as a leading cause of mortality in the pediatric population. Such trauma frequently induces severe damage to parenchymal organs as a result of significant external mechanical force. In severe cases, death may occur rapidly when impaired cardiopulmonary function cannot be adequately sustained. Extracorporeal membrane oxygenation (ECMO) plays a critical role in supporting these patients. However, the selection of an anticoagulation strategy remains a decisive factor influencing clinical outcomes. This study aims to evaluate the comparative efficacy of regional anticoagulation using nafamostat mesilate vs. systemic anticoagulation with unfractionated heparin in pediatric patients with trauma undergoing extracorporeal membrane oxygenation (ECMO) support. Methods: In this study, 40 patients hospitalized due to severe trauma and received ECMO assistance were selected as the research subjects. According to the anticoagulation protocol, the patients were divided into the nafamostat mesilate group and the unfractionated heparin (UFH) group. Demographic data, hematological profiles, and coagulation parameters were systematically compared at baseline, 24, and 72 h after admission in patients receiving ECMO support. Clinical outcomes were evaluated based on the following criteria: transfusion requirements, use of coagulation-related agents, incidence of complications, and successful removal. The SPSS 21.0 statistical software was utilized for data statistics. Results: A total of 40 patients were enrolled in this study, 24 cases in the nafamostat mesilate group and 16 cases in the UFH group. There was no statistically significant difference in characteristics of blood cell classification and coagulation-related laboratory parameters at admission. Compared with the nafamostat mesilate group, the UFH group exhibited a higher rate of new-onset active bleeding, circuit thrombosis, and this difference was statistically significant ( Conclusion: In trauma patients during ECMO support, nafamostat mesilate achieves effective anticoagulation comparable to unfractionated heparin (UFH) while significantly lowering the risk of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.